Subscribe to our Newsletters !!


    Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis

    AMSTERDAM, The Netherlands, November 16, 2020 Calypso Biotech, a company developing Interleukin-15-targeted biologics, today announced completion of dosing of first cohort of healthy subjects in the first Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15. “CALY-002 is the lead program of our differentiated pipeline of IL-15-targeting biologics, that we plan